keyword
MENU ▼
Read by QxMD icon Read
search

Oral ribavirin

keyword
https://www.readbyqxmd.com/read/29907366/use-of-ribavirin-in-viruses-other-than-hepatitis-c-a-review-of-the-evidence
#1
German Ramírez-Olivencia, Miriam Estébanez, Francisco Javier Membrillo, Maria Del Carmen Ybarra
Ribavirin is a molecule with antiviral activity against different viruses. In clinical practice, it has made its niche almost exclusively for the treatment of the hepatitisC virus. However, there are other diseases in which it could be of benefit and it has the advantage of being suitable for oral, intravenous and inhaled administration. We conducted a review of the indications of the main drug agencies (Spanish, European and American) and other possible indications, mainly haemorrhagic fevers and coronavirus...
June 12, 2018: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/29899985/effectiveness-and-safety-of-sofosbuvir-ledipasvir-%C3%A2-ribavirin-treatment-in-liver-and-or-renal-transplant-patients-with-chronic-hepatitis-c-a-single-center-experience
#2
Mete Akin, Osman Cagin Buldukoglu, Haydar Adanir, Inci Suleymanlar, Dinc Dincer, Bulent Yildirim
Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated. Materials and methods: A total of 23 liver and/or renal transplant patients who received sofosbuvir/ledipasvir ± ribavirin for chronic hepatitis C over 12 or 24 weeks were enrolled in the study...
2018: SAGE Open Medicine
https://www.readbyqxmd.com/read/29897788/zinc-a-potential-antiviral-against-hepatitis-e-virus-infection
#3
Nidhi Kaushik, Saumya Anang, Krishna Priya Ganti, Milan Surjit
Hepatitis E virus (HEV) is a major cause of viral hepatitis worldwide. Owing to its feco oral transmission route, sporadic as well as epidemic outbreaks recurrently occur. No specific antiviral therapy is available against the disease caused by HEV. Broad spectrum antivirals such as ribavirin and interferon alfa are prescribed in severe and chronic HEV cases. However, the side effects, cost, and limitations of usage render the available treatment unsuitable for several categories of patients. We recently reported the ability of zinc to inhibit viral replication in mammalian cell culture models of HEV infection...
June 13, 2018: DNA and Cell Biology
https://www.readbyqxmd.com/read/29871018/management-of-hcv-related-liver-disease-in-hemophilia-and-thalassemia
#4
Maria Grazia Rumi, Vito Di Marco, Massimo Colombo
Chronic infection with the hepatitis C virus (HCV) has long been the dominant complication of substitution therapy in patients with inherited blood disorders and the cause of anticipated death due to end-stage liver disease. In hemophilia, transmission of HCV with clotting factors concentrates started to be curbed in the mid-1980s following the adoption of procedures of virus inactivation of concentrates based on heat, whereas in the 1990s treatment of HCV infection with interferon monotherapy was attempted, however, with little success...
May 2018: Seminars in Liver Disease
https://www.readbyqxmd.com/read/29848841/two-neuropsychiatric-cases-seropositive-for-bornavirus-improved-by-ribavirin
#5
Hidenori Matsunaga, Akio Fukumori, Kohji Mori, Tomoyuki Honda, Takeshi Uema, Keizo Tomonaga
While we had previously detected anti-bornavirus antibodies via radioligand assay in psychiatric patients, we had not examined the viral pathogenicity in these individuals. Herein, we present two psychiatric patients who were seropositive for bornavirus and whose treatment-resistant symptoms improved by oral administration of ribavirin, a broad-spectrum antiviral agent. Cerebrospinal fluid analysis indicated that the ribavirin affected the central nervous system of these patients. Ribavirin ameliorated intermittent involuntary head shaking, which is reminiscent of a symptom observed in bornavirus-infected animals...
May 31, 2018: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29807402/-clinical-value-of-pegylated-interferon-%C3%AE-plus-ribavirin-based-therapy-in-antiviral-treatment-of-chronic-hepatitis-c-in-china
#6
F Zhu, Q Y Zhang, D Z Zhang
Chronic hepatitis C virus (HCV) infection is one of the most common causes of liver cirrhosis and hepatocellular carcinoma in China. The older standard treatment regimen for chronic hepatitis C was the pegylated interferon-alfa plus ribavirin(PR). Now newer oral medications called direct antiviral agents (DAAs) has been gradually changed to PR-based DAAs and interferon-free, oral DAAs; making chronic hepatitis C a curable disease. This article intends to expound the advantages and disadvantages of PR-based therapy and provide reference for the treatment of chronic hepatitis C...
March 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29804390/-impression-of-direct-acting-antiviral-agents-in-the-treatment-of-recurrent-hepatocellular-carcinoma-related-to-chronic-hepatitis-c
#7
X H Zhang, Z L Gao
The treatment of chronic hepatitis C has gradually entered into the era of direct-acting antiviral agents (DAAs) from the era of pegylated interferon-α combined with ribavirin, which has a high curative effect, good tolerability, and complete patient-friendly oral form of administration. Sustained virologic response (SVR) acquired by pegylated interferon-α plus ribavirin therapy has been widely recognized by scholars in reducing the recurrence of primary liver cancer and liver cancer, especially in cirrhotic patients...
March 20, 2018: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29780847/community-acquired-respiratory-paramyxovirus-infection-after-allogeneic-hematopoietic-cell-transplantation-a-single-center-experience
#8
Yasmin Spahr, Sarah Tschudin-Sutter, Veronika Baettig, Francesca Compagno, Michael Tamm, Jörg Halter, Sabine Gerull, Jakob Passweg, Hans H Hirsch, Nina Khanna
Background: Paramyxoviruses include respiratory syncytial virus (RSV), parainfluenza virus (PIV), and human metapneumovirus (MPV), which may cause significant respiratory tract infectious disease (RTID) and mortality after allogeneic hematopoietic cell transplantation (HCT). However, clinical data regarding frequency and outcome are scarce. Methods: We identified all paramyxovirus RTIDs in allogeneic HCT recipients diagnosed by multiplex polymerase chain reaction between 2010 and 2014...
May 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#9
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29724249/crimean-congo-hemorrhagic-fever-with-hepatic-impairment-and-vaginal-hemorrhage-a-case-report
#10
Ermira Muco, Najada Como, Siva Bino, Arjan Harxhi, Pellumb Pipero, Majlinda Kota, Jonida Mehmeti, Arta Kushi, Dhimiter Kraja
BACKGROUND: Crimean-Congo hemorrhagic fever is a tick-borne disease described in more than 30 countries in Europe, Asia, and Africa. Albania is located in the southwestern part of the Balkan Peninsula. In 1986, the first case of Crimean-Congo hemorrhagic fever was registered, and cases of patients with hemorrhagic fever are rising, and most of them present in a serious condition, when the mortality rate is very high. In districts like Mirdite, Lezhe, Gjirokaster, Skrapar, Erseke, and Kukes, there is delineated human-to-human transmission...
May 4, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29716855/effect-of-black-seed-oil-supplementation-on-selected-immunological-hematological-and-iron-status-parameters-in-ribavirin-treated-female-albino-rats
#11
H A Abd-Elmonem
Ribavirin has been found to enhance the anti HCV potential of pegylated interferon and sovaldi. However its use was associated with impact on the hemopoietic system and iron status. The hemopoietic toxicity, sometimes forced patients to reduce the dosage or to discontinue treatment in rare occasions. The main purpose of the present study was to assess the potential of black seed oil, a known potent antioxidant, to ameliorate the negative impact of ribavirin on hematological indices, iron status and natural immunity in rats...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29694729/treatment-of-hepatitis-c-virus-infection-in-patients-with-mixed-cryoglobulinemic-syndrome-and-cryoglobulinemic-glomerulonephritis
#12
REVIEW
Stephanie M Rutledge, Raymond T Chung, Meghan E Sise
Cryoglobulinemia is a common extrahepatic manifestation of infection with hepatitis C virus (HCV). When signs and symptoms of systemic vasculitis or glomerulonephritis occur in the presence of circulating cryoglobulins, this syndrome is called "mixed cryoglobulinemia syndrome" (MCS). Historically, interferon-based therapies in HCV have been associated with lower rates of viral cure in patients with MCS than in the general HCV-infected population. The advent of direct-acting antiviral therapies have revolutionized the treatment of HCV, dramatically increasing rates of cure...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29664710/analysis-of-host-and-viral-related-factors-associated-to-direct-acting-antiviral-response-in-hepatitis-c-virus-patients
#13
Hafsa Aziz, Muneeba Aziz, Muzaffar Lateef Gill
Hepatitis C virus (HCV) signifies an important health issue as it is a globally prevalent pathogen and poses a great threat to human health. Direct antiviral therapy became a landmark in treatment against chronic HCV infection as they have proven to increase sustained virological response (SVR) rate, provide shortened and simplified regimens. This study aimed to evaluate efficacy of Sofosbuvir and classify factors of treatment success and their function in therapy continuation decision. We studied host and viral factors in 310 patients who received Sofosbuvir (DAA) at a dose of 400 mg daily along with ribavirin 10 mg/kg body weight for 24 weeks and followed by 12 weeks after completion of treatment...
April 2018: Viral Immunology
https://www.readbyqxmd.com/read/29663115/sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-for-treatment-of-chronic-hcv-genotype-4-patients-real-life-experience
#14
G Shiha, R Soliman, M ElBasiony, A A Hassan, N N H Mikhail
INTRODUCTION: New regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with or without ribavirin (800-1000 mg) in treating chronic hepatitis C genotype 4 patients. METHODS: This is an open-label observational study that describes the effect of 12 week or 24 weeks of daily oral Sofosbuvir (SOF) 400 mg plus Daclatasvir (DCV) 60 mg with or without ribavirin (RBV) with dose adjustment if indicated...
April 16, 2018: Hepatology International
https://www.readbyqxmd.com/read/29628768/outcomes-and-predictors-of-treatment-response-with-sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-in-egyptian-patients-with-genotype-4-hepatitis-c-virus-infection
#15
Ossama A Ahmed, Mohamed A Elsebaey, Mohamed Hassan A Fouad, Heba Elashry, Ahmed I Elshafie, Ahmed A Elhadidy, Noha E Esheba, Mohammed H Elnaggar, Shaimaa Soliman, Sherief Abd-Elsalam
Background and aims: Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3, while published data regarding its real-life application in the treatment of genotype 4 is lacking. Therefore, we conducted this study to assess the outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection...
2018: Infection and Drug Resistance
https://www.readbyqxmd.com/read/29596108/hepatocellular-carcinoma-after-sustained-virological-response-with-interferon-free-regimens-in-hiv-hcv-coinfected-patients
#16
Nicolás Merchante, Francisco Rodríguez-Arrondo, Boris Revollo, Esperanza Merino, Sofía Ibarra, María J Galindo, Marta Montero, Miguel García-Deltoro, Antonio Rivero-Juárez, Francisco Téllez, Marcial Delgado-Fernández, María J Ríos-Villegas, María A García, Francisco J Vera-Méndez, Guillermo Ojeda-Burgos, Miguel A López-Ruz, Luis Metola, Mohamed Omar, María Remedios Alemán-Valls, Koldo Aguirrebengoa, Joseba Portu, Miguel Raffo, Juan Macías, Juan A Pineda
OBJECTIVE: To assess the possible association between the use of direct antiviral agents (DAA) and the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients. METHODS: The GEHEP-002 cohort recruits HCC cases in HIV-infected patients from 32 centers from Spain. Three analyses were performed: the proportion of HCC cases after sustained virological response (SVR) and the evolution of this proportion over time, the frequency of HCC after SVR in HIV/HCV-coinfected patients with cirrhosis, and the probability of HCC recurrence after curative therapies among those undergoing HCV therapy...
March 28, 2018: AIDS
https://www.readbyqxmd.com/read/29595065/protease-inhibitor-therapy-for-hepatitis-c-virus-infection
#17
P de Leuw, C Stephan
The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and tolerability...
April 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29589331/population-pharmacokinetic-analysis-of-asunaprevir-in-subjects-with-hepatitis-c-virus-infection
#18
Li Zhu, Hanbin Li, Phyllis Chan, Timothy Eley, Yash Gandhi, Marc Bifano, Mayu Osawa, Takayo Ueno, Eric Hughes, Malaz AbuTarif, Richard Bertz, Tushar Garimella
INTRODUCTION: Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection. METHODS: A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who received ASV either as part of the DUAL regimen with daclatasvir or as part of the QUAD regimen with daclatasvir and peg-interferon/ribavirin. RESULTS: A two-compartment model with first-order elimination from the central compartment, an induction effect on clearance, and an absorption model consisted of zero-order release followed by first-order absorption adequately described ASV PK after oral administration...
March 27, 2018: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/29582685/-real-life-experience-with-direct-acting-antiviral-agents-for-hepatitis-c-virus-in-end-stage-renal-disease
#19
Rebeca García-Agudo, Sami Aoufi-Rabih, Mercedes Salgueira-Lazo, Carmen González-Corvillo, Fabrizio Fabrizi
BACKGROUND AND AIMS: The advent of direct-acting antiviral agents promises to change the management of hepatitis C in patients with end-stage renal disease, a patient group where the treatment of hepatitis C was historically challenging. We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a 'real-world' group of patients with end-stage renal disease. METHODS: We performed a single-arm, multi-centre study in a cohort (n=30) of patients with advanced chronic kidney disease (mostly on dialysis) who underwent antiviral therapy with direct-acting antiviral agents...
March 1, 2018: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/29566611/treatment-of-hcv-in-the-department-of-corrections-in-the-era-of-oral-medications
#20
Richard K Sterling, Reena Cherian, Shawn Lewis, Kathleen Genther, Carolyn Driscoll, Kelly Martin, Mary Beth Goode, Scott Matherly, Mohammad S Siddiqui, Velimir A Luketic, R Todd Stravitz, Puneet Puri, Hannah Lee, Paula Smith, Vaishali Patel, Arun J Sanyal
Chronic hepatitis C virus (HCV) is widely prevalent in the Virginia Department of Corrections (DOC). However, sustained virologic response (SVR) with all oral direct-acting antiviral (DAA) therapy is unknown. HCV treatment was provided through telemedicine following guidelines of the American Association for the Study of Liver Diseases and Infectious Diseases Society of America. SVR12 in the DOC was compared in two control groups: privately insured and indigent patients receiving care in HCV treatment clinics by the same providers during the same time period...
April 2018: Journal of Correctional Health Care
keyword
keyword
89557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"